Xiamen Amoytop Biotech Co., Ltd. (688278.SS)
CNY 78.14
(-2.42%)
CNY 78.14
(-2.42%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 479.68 Million CNY | 32.89% |
| 2022 | 360.95 Million CNY | 37.29% |
| 2021 | 262.91 Million CNY | 36.7% |
| 2020 | 192.33 Million CNY | -15.0% |
| 2019 | 226.27 Million CNY | 8.52% |
| 2018 | 208.5 Million CNY | 35.51% |
| 2017 | 153.86 Million CNY | -6.46% |
| 2016 | 164.49 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 421.7 Million CNY | -12.09% |
| 2024 Q2 | 353.22 Million CNY | -16.24% |
| 2024 Q3 | 418.76 Million CNY | 18.56% |
| 2023 Q4 | 479.68 Million CNY | 7.21% |
| 2023 Q3 | 447.43 Million CNY | 31.33% |
| 2023 Q1 | 353.23 Million CNY | -2.14% |
| 2023 FY | 479.68 Million CNY | 32.89% |
| 2023 Q2 | 340.69 Million CNY | -3.55% |
| 2022 Q2 | 280.07 Million CNY | 2.7% |
| 2022 Q1 | 272.69 Million CNY | 3.72% |
| 2022 Q3 | 297.65 Million CNY | 6.28% |
| 2022 FY | 360.95 Million CNY | 37.29% |
| 2022 Q4 | 360.95 Million CNY | 21.27% |
| 2021 Q1 | 185.48 Million CNY | -3.56% |
| 2021 Q2 | 205.83 Million CNY | 10.97% |
| 2021 Q4 | 262.91 Million CNY | 9.9% |
| 2021 Q3 | 239.24 Million CNY | 16.23% |
| 2021 FY | 262.91 Million CNY | 36.7% |
| 2020 Q4 | 192.33 Million CNY | 13.37% |
| 2020 Q1 | 218.09 Million CNY | -3.61% |
| 2020 FY | 192.33 Million CNY | -15.0% |
| 2020 Q3 | 169.65 Million CNY | -15.71% |
| 2020 Q2 | 201.26 Million CNY | -7.71% |
| 2019 Q3 | 210.06 Million CNY | 3.11% |
| 2019 FY | 226.27 Million CNY | 8.52% |
| 2019 Q4 | 226.27 Million CNY | 7.71% |
| 2019 Q1 | - CNY | -100.0% |
| 2019 Q2 | 203.74 Million CNY | 0.0% |
| 2018 FY | 208.5 Million CNY | 35.51% |
| 2018 Q4 | 208.5 Million CNY | 0.0% |
| 2017 FY | 153.86 Million CNY | -6.46% |
| 2016 FY | 164.49 Million CNY | 0.0% |